Oxurion NV
XBRU:OXUR

Watchlist Manager
Oxurion NV Logo
Oxurion NV
XBRU:OXUR
Watchlist
Price: 0.2975 EUR 5.31% Market Closed
Market Cap: 397.5k EUR
Have any thoughts about
Oxurion NV?
Write Note

Intrinsic Value

OXUR's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one OXUR stock under the Base Case scenario is 1.768 EUR. Compared to the current market price of 0.2975 EUR, Oxurion NV is Undervalued by 83%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

OXUR Intrinsic Value
1.768 EUR
Undervaluation 83%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Oxurion NV

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for OXUR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about OXUR?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Oxurion NV

Provide an overview of the primary business activities
of Oxurion NV.

What unique competitive advantages
does Oxurion NV hold over its rivals?

What risks and challenges
does Oxurion NV face in the near future?

Summarize the latest earnings call
of Oxurion NV.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Oxurion NV.

Provide P/S
for Oxurion NV.

Provide P/E
for Oxurion NV.

Provide P/OCF
for Oxurion NV.

Provide P/FCFE
for Oxurion NV.

Provide P/B
for Oxurion NV.

Provide EV/S
for Oxurion NV.

Provide EV/GP
for Oxurion NV.

Provide EV/EBITDA
for Oxurion NV.

Provide EV/EBIT
for Oxurion NV.

Provide EV/OCF
for Oxurion NV.

Provide EV/FCFF
for Oxurion NV.

Provide EV/IC
for Oxurion NV.

What are the Revenue projections
for Oxurion NV?

How accurate were the past Revenue estimates
for Oxurion NV?

What are the Net Income projections
for Oxurion NV?

How accurate were the past Net Income estimates
for Oxurion NV?

What are the EPS projections
for Oxurion NV?

How accurate were the past EPS estimates
for Oxurion NV?

What are the EBIT projections
for Oxurion NV?

How accurate were the past EBIT estimates
for Oxurion NV?

Compare the revenue forecasts
for Oxurion NV with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Oxurion NV and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Oxurion NV against its competitors.

Analyze the profit margins
(gross, operating, and net) of Oxurion NV compared to its peers.

Compare the P/E ratios
of Oxurion NV against its peers.

Discuss the investment returns and shareholder value creation
comparing Oxurion NV with its peers.

Analyze the financial leverage
of Oxurion NV compared to its main competitors.

Show all profitability ratios
for Oxurion NV.

Provide ROE
for Oxurion NV.

Provide ROA
for Oxurion NV.

Provide ROIC
for Oxurion NV.

Provide ROCE
for Oxurion NV.

Provide Gross Margin
for Oxurion NV.

Provide Operating Margin
for Oxurion NV.

Provide Net Margin
for Oxurion NV.

Provide FCF Margin
for Oxurion NV.

Show all solvency ratios
for Oxurion NV.

Provide D/E Ratio
for Oxurion NV.

Provide D/A Ratio
for Oxurion NV.

Provide Interest Coverage Ratio
for Oxurion NV.

Provide Altman Z-Score Ratio
for Oxurion NV.

Provide Quick Ratio
for Oxurion NV.

Provide Current Ratio
for Oxurion NV.

Provide Cash Ratio
for Oxurion NV.

What is the historical Revenue growth
over the last 5 years for Oxurion NV?

What is the historical Net Income growth
over the last 5 years for Oxurion NV?

What is the current Free Cash Flow
of Oxurion NV?

Discuss the annual earnings per share (EPS)
trend over the past five years for Oxurion NV.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Oxurion NV

Current Assets 2.7m
Cash & Short-Term Investments 1.7m
Receivables 1.1m
Non-Current Assets 3.8m
PP&E 245k
Other Non-Current Assets 3.6m
Current Liabilities 19.6m
Accounts Payable 4.9m
Other Current Liabilities 14.7m
Non-Current Liabilities 129k
Long-Term Debt 117k
Other Non-Current Liabilities 12k
Efficiency

Earnings Waterfall
Oxurion NV

Revenue
263k EUR
Cost of Revenue
-159k EUR
Gross Profit
104k EUR
Operating Expenses
-12.1m EUR
Operating Income
-12m EUR
Other Expenses
-7m EUR
Net Income
-19m EUR

Free Cash Flow Analysis
Oxurion NV

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

OXUR Profitability Score
Profitability Due Diligence

Oxurion NV's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional ROE
Positive Gross Profit
ROE is Increasing
35/100
Profitability
Score

Oxurion NV's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

OXUR Solvency Score
Solvency Due Diligence

Oxurion NV's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
31/100
Solvency
Score

Oxurion NV's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

OXUR Price Targets Summary
Oxurion NV

There are no price targets for OXUR.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for OXUR?

Click here to dive deeper.

Dividends

Oxurion NV
does not pay dividends
Shareholder Yield

Current shareholder yield for OXUR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Oxurion NV Logo
Oxurion NV

Country

Belgium

Industry

Biotechnology

Market Cap

397.5k EUR

Dividend Yield

0%

Description

Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. The company is headquartered in Heverlee, Vlaams-Brabant and currently employs 42 full-time employees. The company went IPO on 2006-07-07. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The firm is active domestically, as well as operates through offices located in the United States and Ireland.

Contact

VLAAMS-BRABANT
Heverlee
Gaston Geenslaan 1
+3216751310.0
www.oxurion.com

IPO

2006-07-07

Employees

42

Officers

CEO, CFO & Executive Director
Mr. Pascal Ghoson
Chief Scientific Officer
Mr. Philippe Barbeaux Ph.D.
Chief Development Officer
Dr. Andy De Deene M.B.A., M.D.

See Also

Discover More
What is the Intrinsic Value of one OXUR stock?

The intrinsic value of one OXUR stock under the Base Case scenario is 1.768 EUR.

Is OXUR stock undervalued or overvalued?

Compared to the current market price of 0.2975 EUR, Oxurion NV is Undervalued by 83%.

Back to Top